Skip to main content
Top
Published in: Rheumatology International 2/2015

Open Access 01-02-2015 | Review Article

Sjögren’s syndrome: still not fully understood disease

Authors: Maria Maślińska, Małgorzata Przygodzka, Brygida Kwiatkowska, Katarzyna Sikorska-Siudek

Published in: Rheumatology International | Issue 2/2015

Login to get access

Abstract

Primary Sjögren's syndrome is an autoimmune disorder with external exocrine glands dysfunction and multiorgan involvement. The pathogenesis of primary Sjogren’s syndrome is still unclear; however, our knowledge of the involvement of different cells (e.g., B and T cells, macrophages and dendritic cells) and pathways (BAFF/APRIL and interferons) leading to the development of autoimmunity is continually expanding. For clinicians, the most frequent symptoms are dryness of eyes and mouth, but often the patients have musculoskeletal symptoms and systemic manifestations. However, the increased risk of lymphoproliferative disorders in this group of patients, most commonly B-cell marginal zone lymphoma, is particularly important. Recent separation of IgG4-related diseases and attempts to create further diagnostic criteria for pSS testify to the difficulties, and at the same time a large interest, in understanding the disease so as to allow the effective treatment. This article draws attention to the problems faced by the clinician wishing to securely identify pSS by using accurate laboratory biomarkers and useful imaging tools and predict the development of complications associated with this, still not fully understood, autoimmune disease.
Literature
1.
go back to reference Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM (2012) HLA and Sjögren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 11(4):281–287PubMedCrossRef Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM (2012) HLA and Sjögren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 11(4):281–287PubMedCrossRef
2.
go back to reference Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y (2012) Sjögren’s syndrome, the old and the new. Best Pract Clin Rheum 26:105–117CrossRef Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y (2012) Sjögren’s syndrome, the old and the new. Best Pract Clin Rheum 26:105–117CrossRef
3.
go back to reference Johnson EO, Skopouli FN, Moutsopoulos HM (2000) Neuroendocrine manifestations in Sjögren’s syndrome. Rheum Dis Clin North Am 26(4):927–949PubMedCrossRef Johnson EO, Skopouli FN, Moutsopoulos HM (2000) Neuroendocrine manifestations in Sjögren’s syndrome. Rheum Dis Clin North Am 26(4):927–949PubMedCrossRef
4.
go back to reference Tzioufas AG, Tsonis J, Moutsopoulos HM (2008) Neuroendocrine dysfunction in Sjogren’s syndrome. NeuroImmunoModulation 15(1):37–45PubMed Tzioufas AG, Tsonis J, Moutsopoulos HM (2008) Neuroendocrine dysfunction in Sjogren’s syndrome. NeuroImmunoModulation 15(1):37–45PubMed
5.
go back to reference Bikker A, Moret FM, Kruize AA, Bijlsma JW, Lafeber FP, van Roon (2002) IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology (Oxford) 51(6):996–1005CrossRef Bikker A, Moret FM, Kruize AA, Bijlsma JW, Lafeber FP, van Roon (2002) IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology (Oxford) 51(6):996–1005CrossRef
6.
go back to reference Ciccia F, Alessandro R, Rodolico V et al (2013) IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren’s syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes. JA Rheumatology (Oxford) 52(6):1009–1017CrossRef Ciccia F, Alessandro R, Rodolico V et al (2013) IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren’s syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes. JA Rheumatology (Oxford) 52(6):1009–1017CrossRef
7.
go back to reference Kang KY, Kim HO, Kwok SK, Ju JH et al (2011) Impact of interleukin-21 in the pathogenesis of primary Sjögren’s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 13(5):R179. doi:10.1186/ar3504.Epub PubMedCentralPubMedCrossRef Kang KY, Kim HO, Kwok SK, Ju JH et al (2011) Impact of interleukin-21 in the pathogenesis of primary Sjögren’s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 13(5):R179. doi:10.​1186/​ar3504.​Epub PubMedCentralPubMedCrossRef
8.
go back to reference Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, Takeuchi T (2011) Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren’s syndrome. Arthritis Res Ther 13(5):R170PubMedCentralPubMedCrossRef Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, Takeuchi T (2011) Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren’s syndrome. Arthritis Res Ther 13(5):R170PubMedCentralPubMedCrossRef
9.
go back to reference Cornec D, Saraux A, Pers JO et al (2014) Diagnostic occuracy of blood B-cell subset profiling and autoimmunity markers in Sjogren’s syndrome. Arthritis Res Ther 16:R15PubMedCentralPubMedCrossRef Cornec D, Saraux A, Pers JO et al (2014) Diagnostic occuracy of blood B-cell subset profiling and autoimmunity markers in Sjogren’s syndrome. Arthritis Res Ther 16:R15PubMedCentralPubMedCrossRef
10.
go back to reference Bohnhorst JØ, Bjørgan MB, Thoen JE, Natvig JB, Thompson KM (2001) Bm1–Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren’s syndrome. Immunology 167(7):3610–3618CrossRef Bohnhorst JØ, Bjørgan MB, Thoen JE, Natvig JB, Thompson KM (2001) Bm1–Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren’s syndrome. Immunology 167(7):3610–3618CrossRef
12.
go back to reference Baldini C, Delle Sedie A, Luciano N, Pepe P, Ferro F, Talarico R, Tani C, Mosca M (2013) Vitamin D in “early” primary Sjögren’s syndrome: does it play a role in influencing disease phenotypes? Rheumatol Int. doi:10.1007/s00296-013-2872-3 Baldini C, Delle Sedie A, Luciano N, Pepe P, Ferro F, Talarico R, Tani C, Mosca M (2013) Vitamin D in “early” primary Sjögren’s syndrome: does it play a role in influencing disease phenotypes? Rheumatol Int. doi:10.​1007/​s00296-013-2872-3
13.
go back to reference Agmon-Levin N, Kivity S, Tzioufas AG et al (2012) Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. J Autoimmun 39(3):234–239PubMedCrossRef Agmon-Levin N, Kivity S, Tzioufas AG et al (2012) Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. J Autoimmun 39(3):234–239PubMedCrossRef
14.
go back to reference Kyriakidis NC, Kapsogeorgou EK, Tzioufas AG (2003) A comprehensive review of autoantibodies in primary Sjogren’s syndrome: clinical phenotypes and regulatory mechanisms. J Autoimmun 51C:67–74 Kyriakidis NC, Kapsogeorgou EK, Tzioufas AG (2003) A comprehensive review of autoantibodies in primary Sjogren’s syndrome: clinical phenotypes and regulatory mechanisms. J Autoimmun 51C:67–74
15.
go back to reference Sumida T, Tsuboi H, Iizuka M, Hirota T, Asashima H, Matsumoto I (2014) The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren’s syndrome: a critical review. J Autoimmun (4). doi:10.1016/j.jaut.2013.12.012 Sumida T, Tsuboi H, Iizuka M, Hirota T, Asashima H, Matsumoto I (2014) The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren’s syndrome: a critical review. J Autoimmun (4). doi:10.​1016/​j.​jaut.​2013.​12.​012
16.
go back to reference Sumida T, Lizuka M, Asashima H, Tsuboi H, Matsumoto I (2012) Pathogenic role of anti-M3 muscarinic acetylcholine receptor immune response in Sjögren’s syndrome. Presse Med 41(9 Pt 2):e461–e466PubMedCrossRef Sumida T, Lizuka M, Asashima H, Tsuboi H, Matsumoto I (2012) Pathogenic role of anti-M3 muscarinic acetylcholine receptor immune response in Sjögren’s syndrome. Presse Med 41(9 Pt 2):e461–e466PubMedCrossRef
17.
18.
go back to reference Karp JK, Akpek EK, Anders RA (2010) Autoimmune hepatitis in patients with primary Sjögren’s syndrome: a series of two-hundred and two patients. Int J Clin Exp Pathol 25;3(6):582–6 Karp JK, Akpek EK, Anders RA (2010) Autoimmune hepatitis in patients with primary Sjögren’s syndrome: a series of two-hundred and two patients. Int J Clin Exp Pathol 25;3(6):582–6
19.
go back to reference Ono M, Ono M, Watanabe K, Miyashita Y et al (1999) A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases. J Dermatol Sci 21(3):183–186PubMedCrossRef Ono M, Ono M, Watanabe K, Miyashita Y et al (1999) A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases. J Dermatol Sci 21(3):183–186PubMedCrossRef
20.
go back to reference Atzeni F, Sarzi-Puttini P, Lama N et al (2008) Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 10(3):R51PubMedCentralPubMedCrossRef Atzeni F, Sarzi-Puttini P, Lama N et al (2008) Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 10(3):R51PubMedCentralPubMedCrossRef
21.
go back to reference Shen L, Suresh L, Lindemann M et al (2012) Novel autoantibodies in Sjogren’s syndrome. Clin Immunol 145(3):251–255PubMedCrossRef Shen L, Suresh L, Lindemann M et al (2012) Novel autoantibodies in Sjogren’s syndrome. Clin Immunol 145(3):251–255PubMedCrossRef
22.
go back to reference D’Arbonneau F, Ansart S, Le Berre R, Dueymes M, Youinou P, Pennec YL (2003) Thyroid dysfunction in primary Sjögren’s syndrome: a long-term followup study. Arthritis Rheum 49(6):804–809PubMedCrossRef D’Arbonneau F, Ansart S, Le Berre R, Dueymes M, Youinou P, Pennec YL (2003) Thyroid dysfunction in primary Sjögren’s syndrome: a long-term followup study. Arthritis Rheum 49(6):804–809PubMedCrossRef
23.
go back to reference Tunc R, Gonen M, Acbay O, Hamuryudan V, Yazici H (2004) Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjögren’s syndrome: a case–control study. Ann Rheum Dis 63(5):575–577PubMedCentralPubMedCrossRef Tunc R, Gonen M, Acbay O, Hamuryudan V, Yazici H (2004) Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjögren’s syndrome: a case–control study. Ann Rheum Dis 63(5):575–577PubMedCentralPubMedCrossRef
24.
go back to reference Shiboski SC, Shiboski CH, Criswell L et al (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) A;64(4):475–87 Shiboski SC, Shiboski CH, Criswell L et al (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) A;64(4):475–87
25.
go back to reference Vitali C, Bootsma H, Bowman SJ et al (2013) Classification criteria for Sjögren’s syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 72:476–478PubMedCrossRef Vitali C, Bootsma H, Bowman SJ et al (2013) Classification criteria for Sjögren’s syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 72:476–478PubMedCrossRef
26.
go back to reference Rasmussen A, Ice JA, Li H et al (2014) Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterized sicca cohort. Ann Rheum Dis 73(1). doi:10.1136/annrheumdis-2013-203845 Rasmussen A, Ice JA, Li H et al (2014) Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterized sicca cohort. Ann Rheum Dis 73(1). doi:10.​1136/​annrheumdis-2013-203845
27.
go back to reference Speight PM, Kaul A, Melsom RD et al (1992) Measurement of whole unstimulated salivary flow in the diagnosis of Sjögren’s syndrome. Ann Rheum Dis 52:499–502CrossRef Speight PM, Kaul A, Melsom RD et al (1992) Measurement of whole unstimulated salivary flow in the diagnosis of Sjögren’s syndrome. Ann Rheum Dis 52:499–502CrossRef
28.
go back to reference Theander E, Mandl T. (2013) Primary sjogrens syndrome : the diagnostic and prognostic value of salivary gland ultrasonography using simplified scoring system. Arthritis Care Res (Hoboken) 10. doi:10.1002/acr.22264 Theander E, Mandl T. (2013) Primary sjogrens syndrome : the diagnostic and prognostic value of salivary gland ultrasonography using simplified scoring system. Arthritis Care Res (Hoboken) 10. doi:10.​1002/​acr.​22264
29.
go back to reference Hocevar A, Amrozic A, Rozman B, Kveder T, Tomsic M (2005) Ultrasonographic changes of major salivary glands in primary Sjogren’s syndrome. Diagnostic value of the novel scoring system. Rheumatology (Oxford) 44(6):768–772CrossRef Hocevar A, Amrozic A, Rozman B, Kveder T, Tomsic M (2005) Ultrasonographic changes of major salivary glands in primary Sjogren’s syndrome. Diagnostic value of the novel scoring system. Rheumatology (Oxford) 44(6):768–772CrossRef
30.
go back to reference Varela-Centelles P, Seoane-Romero JM, Sánchez-Sánchez M, González-Mosquera A, Diz-Dios P, Seoane J (2014) Minor salivary gland biopsy in Sjögren’s syndrome: a review and introduction of a new tool to ease the procedure. Med Oral Patol Oral Cir Bucal 1;19(1):e20–e23 Varela-Centelles P, Seoane-Romero JM, Sánchez-Sánchez M, González-Mosquera A, Diz-Dios P, Seoane J (2014) Minor salivary gland biopsy in Sjögren’s syndrome: a review and introduction of a new tool to ease the procedure. Med Oral Patol Oral Cir Bucal 1;19(1):e20–e23
31.
go back to reference Lida Santiago M, Seisdedos MR, García Salinas RN et al (2012) Frequency of complications and usefulness of the minor salivary gland biopsy. Reumatol Clin 8(5):255–258 Epub 2012 Jul 6PubMedCrossRef Lida Santiago M, Seisdedos MR, García Salinas RN et al (2012) Frequency of complications and usefulness of the minor salivary gland biopsy. Reumatol Clin 8(5):255–258 Epub 2012 Jul 6PubMedCrossRef
32.
go back to reference Theander E, Vasaitis L, Baecklund E et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis 70(8):1363–1368PubMedCentralPubMedCrossRef Theander E, Vasaitis L, Baecklund E et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis 70(8):1363–1368PubMedCentralPubMedCrossRef
33.
go back to reference Okazaki K, Umehara H (2012) Are classification criteria for IgG4-RD now possible? The concept of IgG4 related diseases and proposal of comprehensive diagnostic criteria in Japan. Int J Rheum. doi:10.1155/2012/357971 Okazaki K, Umehara H (2012) Are classification criteria for IgG4-RD now possible? The concept of IgG4 related diseases and proposal of comprehensive diagnostic criteria in Japan. Int J Rheum. doi:10.​1155/​2012/​357971
34.
go back to reference Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch JA, Toussirot E, Medina F, Rosas J, Anaya JM, Font J, SS-HCV Study Group (2005) Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 84(2):81–99CrossRef Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch JA, Toussirot E, Medina F, Rosas J, Anaya JM, Font J, SS-HCV Study Group (2005) Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 84(2):81–99CrossRef
35.
go back to reference Madaliński K, Godzik P, Zimmermann-Górska I et al (2009) Anti-HCV and HCV-RNA in patients with primary Sjogren’s syndrome. Przegl Epidemiol 63:299–304PubMed Madaliński K, Godzik P, Zimmermann-Górska I et al (2009) Anti-HCV and HCV-RNA in patients with primary Sjogren’s syndrome. Przegl Epidemiol 63:299–304PubMed
36.
go back to reference Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren’s syndrome. Arthritis Rheum 42(8):1765–1772PubMedCrossRef Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren’s syndrome. Arthritis Rheum 42(8):1765–1772PubMedCrossRef
37.
go back to reference Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88(5):284–293CrossRef Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88(5):284–293CrossRef
38.
go back to reference Thiebelmont C, Bertoni F, Copie-Bergman C, Ferreri AJM, Ponzoni M (2013) Chronic inflammation and extra-nodal-zone lymphomas of MALT-type. Semin Cancer Biol 24:33–42CrossRef Thiebelmont C, Bertoni F, Copie-Bergman C, Ferreri AJM, Ponzoni M (2013) Chronic inflammation and extra-nodal-zone lymphomas of MALT-type. Semin Cancer Biol 24:33–42CrossRef
39.
go back to reference Quartuccio L, Isola M, Baldini Ch et al (2013) Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 1–6. doi:10.1016/j.jaut.2013.10.002 Quartuccio L, Isola M, Baldini Ch et al (2013) Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 1–6. doi:10.​1016/​j.​jaut.​2013.​10.​002
40.
go back to reference Baecklund E, Smedbyb KE, Suttonc LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders—what are the driving forces? Semin Cancer Biol 24:61–70PubMedCrossRef Baecklund E, Smedbyb KE, Suttonc LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders—what are the driving forces? Semin Cancer Biol 24:61–70PubMedCrossRef
41.
go back to reference Barclay L (2010) Treatment of primary Sjogren’s syndrome reviewed. JAMA 304:452–460CrossRef Barclay L (2010) Treatment of primary Sjogren’s syndrome reviewed. JAMA 304:452–460CrossRef
42.
go back to reference Meijer JM, Meiners PM, Vissink A et al (2010) Effectivnes of Rituximab treatment in primary Sjögren’s syndrome. Arthritis Rheum 62(4):960–968PubMedCrossRef Meijer JM, Meiners PM, Vissink A et al (2010) Effectivnes of Rituximab treatment in primary Sjögren’s syndrome. Arthritis Rheum 62(4):960–968PubMedCrossRef
43.
go back to reference Mariette X, Seror R, Quartuccio L et al (2013) Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of BELLIS open label phase II study. Ann Rheum Dis 1–6. doi:10.1136/annrheumdis-2013-203991 Mariette X, Seror R, Quartuccio L et al (2013) Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of BELLIS open label phase II study. Ann Rheum Dis 1–6. doi:10.​1136/​annrheumdis-2013-203991
44.
go back to reference Levasque MC (2009) Translational mini-review series on B cell-directed the rapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immun 157:198–208CrossRef Levasque MC (2009) Translational mini-review series on B cell-directed the rapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immun 157:198–208CrossRef
45.
go back to reference Steinfeld SD, Tant L, Burmester GR et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8(4):R129PubMedCentralPubMedCrossRef Steinfeld SD, Tant L, Burmester GR et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8(4):R129PubMedCentralPubMedCrossRef
46.
go back to reference Vossenkämper A, Lutalo PM, Spencer J (2012) Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren’s syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol 167(1):7–14PubMedCentralPubMedCrossRef Vossenkämper A, Lutalo PM, Spencer J (2012) Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren’s syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol 167(1):7–14PubMedCentralPubMedCrossRef
47.
go back to reference Xu J, Wang D, Liu D, Fan Z et al (2012) Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood 11;120(15):3142–51 Xu J, Wang D, Liu D, Fan Z et al (2012) Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood 11;120(15):3142–51
Metadata
Title
Sjögren’s syndrome: still not fully understood disease
Authors
Maria Maślińska
Małgorzata Przygodzka
Brygida Kwiatkowska
Katarzyna Sikorska-Siudek
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3072-5

Other articles of this Issue 2/2015

Rheumatology International 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.